Trial Profile

A Phase 3, Multicenter, Randomized, Double-Blinded and Placebo-Controlled Study Evaluating the Efficacy and Safety of 0.25% HBM9036 (HL036) Ophthalmic Solution Compared to Placebo in Chinese Subjects With Moderate and Severe Dry Eye

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 07 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

28 Apr 2023 According to an HanAll Biopharma media release, Harbour BioMed, a licensed partner of HanAll in China, closed its Phase 3 China study in DED, based on the Independent Data Monitoring Committee's (IDMC) evaluation of the efficacy data from the second interim analysis.
28 Apr 2023 Status changed to discontinued, according to an HanAll Biopharma media release.
23 Feb 2023 Planned End Date changed from 7 Jan 2023 to 7 Apr 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com